Back to Results
First PageMeta Content
Overactive bladder / Urodynamic testing / Urinary incontinence / Urinary retention / Astellas Pharma / Urinary bladder / National Association For Continence / Frequent urination / Percutaneous tibial nerve stimulation / Medicine / Urology / Incontinence


MYRBETRIQ™ (mirabegron), Overactive Bladder Treatment from Astellas, Now Available Through U.S. Pharmacies NORTHBROOK, Ill., Oct. 22, 2012 – Astellas Pharma US, Inc. (“Astellas”), a U.S. subsidiary of Tokyobased
Add to Reading List

Document Date: 2012-10-22 19:12:22

Open Document

File Size: 59,17 KB

Share Result on Facebook

City

Tokyo / NORTHBROOK / /

Company

Tokyobased Astellas Pharma Inc. / Astellas Pharma US Inc. / Astellas Urology Astellas Pharma US Inc. / Astellas Pharma Inc. / /

Country

United States / /

/

Event

FDA Phase / /

IndustryTerm

http /

MedicalCondition

overactive bladder / headache / nasopharyngitis / urinary tract infection / urge urinary incontinence / common cold symptoms / high blood pressure / /

Organization

National Association for Continence / International Continence Society / U.S. Food and Drug Administration / Urology Care Foundation / American Urological Association / /

Person

Paula Mavroudis / Jim Robinson / Allen Seftel / Jenny M. Kite / /

/

Position

council chair / global category leader / senior vice president / Astellas Sales and Marketing / /

Product

Lanoxin / Rythmol / Tambocor / digoxin / Mellaril / MYRBETRIQ™ (mirabegron) / /

ProvinceOrState

Illinois / /

URL

www.fda.gov/medwatch / www.astellas.us / http /

SocialTag